Skip to content
PSA-membrane antibody conjugate shows promise for treating metastatic castration-resistant, taxane-refractory prostate cancer

PSA-membrane antibody conjugate shows promise for treating metastatic castration-resistant, taxane-refractory prostate cancer

Get the podcast

SAN FRANCISCO—A “guided missile” approach to treating metastatic, castration-resistant, taxane-refractory prostate cancer demonstrated success at the 2014 ASCO Genitourinary Cancers Sympos

The Audio Journal of Oncology

SAN FRANCISCO—A “guided missile” approach to treating metastatic, castration-resistant, taxane-refractory prostate cancer demonstrated success at the 2014 ASCO Genitourinary Cancers Symposium. Daniel Petrylak MD of Yale University Medical Center in New Haven CT discussed the clinical potential arising from his group’s study findings: anti-tumor activity and responses of PSA and circulating tumour cells arising from treatment with an immunoconjugate consisting of an antibody to prostate specific membrane antigen bonded to the microtubule-disrupting molecule monomethyl auristatin E (MMAE).

CONTACT:
Daniel Peter Petrylak MD, Yale University Medical Center, New Haven, CT SOURCE:
Abstract No: 8
ABSTRACT TITLE: A phase II trial of prostate-specific membrane antigen antibody drug conjugate (PSMA ADC) in taxane-refractory metastatic castration-resistant prostate cancer (mCRPC).

LINK:
Abstract web link: http://abstracts.asco.org/142/AbstView_142_124080.html

Tags

immuno-conjugatemetastaticprostate cancerPSA membrane antibodyPSA membrane antigen

Next in ASCO 2014

All 7 interviews

Interview 7 of 7

Orteronel shows no survival advantage in metastatic castration-resistant prostate cancer: phase III randomized study finds

Orteronel shows no survival advantage in metastatic castration-resistant prostate cancer: phase III randomized study finds

SAN FRANCISCO—Orteronel — a non-steroidal selective inhibitor of 17,20-lyase — did not achieve a significant improvement in overall survival in 1099 patients randomised to treatment with this “a

6 February 2014

Related Episodes

Which High-Risk Prostate Cancers Need Multimodality Treatment?

Which High-Risk Prostate Cancers Need Multimodality Treatment?

MILAN, Italy—Patients with node-positive prostate cancer being treated with prostatectomy could derive benefit from early multimodality therapy combining androgen deprivation therapy (ADT) with radiot

18 Apr 2017
Gene Assay Predicts Which Patients Need Radiation After Prostatectomy

Gene Assay Predicts Which Patients Need Radiation After Prostatectomy

ARTICLE MILAN, Italy—Genomic testing combined with clinical assessment could be the best way to identify patients with prostate cancer who can benefit from early radiotherapy after prostatectomy, acco

18 Apr 2017